Efficacy and safety of a millimetre wave medical device for pain neuromodulation in peripheral osteoarthritis: a crossover randomised trial
To manage osteoarthritis (OA)-related pain, current guidelines recommend a combination of non-pharmacological and pharmacological treatments. The objective of this study was to assess a millimetre-wave-emitting medical device (MD) for neuromodulation of pain in patients with peripheral OA. In this m...
Saved in:
| Published in: | Rheumatology (Oxford, England) |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
13.09.2025
|
| Subjects: | |
| ISSN: | 1462-0332, 1462-0332 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | To manage osteoarthritis (OA)-related pain, current guidelines recommend a combination of non-pharmacological and pharmacological treatments. The objective of this study was to assess a millimetre-wave-emitting medical device (MD) for neuromodulation of pain in patients with peripheral OA.
In this monocentric, prospective, crossover, randomised controlled trial, 60 patients with peripheral OA affecting joints (ankle, knee, hip, shoulder, elbow, and fingers) and a pain score ≥ 4 on the Visual Analogue Scale (VAS) were recruited and randomly assigned to one of two crossover sequences. The primary outcome was self-assessed pain, while secondary outcomes included life and sleep quality.
Of the 60 patients included, 31 were randomly assigned to the OFF/ON sequence and 29 to the ON/OFF sequence. The baseline mean pain scores for the groups was 6.05 (SD = 1.36) and 6.31 (SD = 1.52) on the VAS, respectively. During the MD use period, the mean daily VAS pain score was 4.57 (SD = 2), compared with 5.32 (SD = 1.77) during the period without MD use. The mean paired difference between periods was 0.74 (SD = 1.77). This difference was statistically significant (p= 0.002). The corresponding effect size was 0.42. No carryover, sequence, or period effects were observed. Secondary outcomes related to quality of life and sleep quality showed significant improvement with MD use. No serious adverse events were reported.
In patients with peripheral OA, regular use of this MD significantly reduced in pain (VAS), improved both quality of life (EQ5D-5L) and sleep quality (VAS). Future research should focus on individualised benefit-risk balance, incorporating patient preferences.
ClinicalTrials.gov; NCT04590079. |
|---|---|
| AbstractList | To manage osteoarthritis (OA)-related pain, current guidelines recommend a combination of non-pharmacological and pharmacological treatments. The objective of this study was to assess a millimetre-wave-emitting medical device (MD) for neuromodulation of pain in patients with peripheral OA.OBJECTIVESTo manage osteoarthritis (OA)-related pain, current guidelines recommend a combination of non-pharmacological and pharmacological treatments. The objective of this study was to assess a millimetre-wave-emitting medical device (MD) for neuromodulation of pain in patients with peripheral OA.In this monocentric, prospective, crossover, randomised controlled trial, 60 patients with peripheral OA affecting joints (ankle, knee, hip, shoulder, elbow, and fingers) and a pain score ≥ 4 on the Visual Analogue Scale (VAS) were recruited and randomly assigned to one of two crossover sequences. The primary outcome was self-assessed pain, while secondary outcomes included life and sleep quality.METHODSIn this monocentric, prospective, crossover, randomised controlled trial, 60 patients with peripheral OA affecting joints (ankle, knee, hip, shoulder, elbow, and fingers) and a pain score ≥ 4 on the Visual Analogue Scale (VAS) were recruited and randomly assigned to one of two crossover sequences. The primary outcome was self-assessed pain, while secondary outcomes included life and sleep quality.Of the 60 patients included, 31 were randomly assigned to the OFF/ON sequence and 29 to the ON/OFF sequence. The baseline mean pain scores for the groups was 6.05 (SD = 1.36) and 6.31 (SD = 1.52) on the VAS, respectively. During the MD use period, the mean daily VAS pain score was 4.57 (SD = 2), compared with 5.32 (SD = 1.77) during the period without MD use. The mean paired difference between periods was 0.74 (SD = 1.77). This difference was statistically significant (p= 0.002). The corresponding effect size was 0.42. No carryover, sequence, or period effects were observed. Secondary outcomes related to quality of life and sleep quality showed significant improvement with MD use. No serious adverse events were reported.RESULTSOf the 60 patients included, 31 were randomly assigned to the OFF/ON sequence and 29 to the ON/OFF sequence. The baseline mean pain scores for the groups was 6.05 (SD = 1.36) and 6.31 (SD = 1.52) on the VAS, respectively. During the MD use period, the mean daily VAS pain score was 4.57 (SD = 2), compared with 5.32 (SD = 1.77) during the period without MD use. The mean paired difference between periods was 0.74 (SD = 1.77). This difference was statistically significant (p= 0.002). The corresponding effect size was 0.42. No carryover, sequence, or period effects were observed. Secondary outcomes related to quality of life and sleep quality showed significant improvement with MD use. No serious adverse events were reported.In patients with peripheral OA, regular use of this MD significantly reduced in pain (VAS), improved both quality of life (EQ5D-5L) and sleep quality (VAS). Future research should focus on individualised benefit-risk balance, incorporating patient preferences.CONCLUSIONIn patients with peripheral OA, regular use of this MD significantly reduced in pain (VAS), improved both quality of life (EQ5D-5L) and sleep quality (VAS). Future research should focus on individualised benefit-risk balance, incorporating patient preferences.ClinicalTrials.gov; NCT04590079.CLINICAL TRIALS REGISTRATIONClinicalTrials.gov; NCT04590079. To manage osteoarthritis (OA)-related pain, current guidelines recommend a combination of non-pharmacological and pharmacological treatments. The objective of this study was to assess a millimetre-wave-emitting medical device (MD) for neuromodulation of pain in patients with peripheral OA. In this monocentric, prospective, crossover, randomised controlled trial, 60 patients with peripheral OA affecting joints (ankle, knee, hip, shoulder, elbow, and fingers) and a pain score ≥ 4 on the Visual Analogue Scale (VAS) were recruited and randomly assigned to one of two crossover sequences. The primary outcome was self-assessed pain, while secondary outcomes included life and sleep quality. Of the 60 patients included, 31 were randomly assigned to the OFF/ON sequence and 29 to the ON/OFF sequence. The baseline mean pain scores for the groups was 6.05 (SD = 1.36) and 6.31 (SD = 1.52) on the VAS, respectively. During the MD use period, the mean daily VAS pain score was 4.57 (SD = 2), compared with 5.32 (SD = 1.77) during the period without MD use. The mean paired difference between periods was 0.74 (SD = 1.77). This difference was statistically significant (p= 0.002). The corresponding effect size was 0.42. No carryover, sequence, or period effects were observed. Secondary outcomes related to quality of life and sleep quality showed significant improvement with MD use. No serious adverse events were reported. In patients with peripheral OA, regular use of this MD significantly reduced in pain (VAS), improved both quality of life (EQ5D-5L) and sleep quality (VAS). Future research should focus on individualised benefit-risk balance, incorporating patient preferences. ClinicalTrials.gov; NCT04590079. |
| Author | Maindet, Caroline Giai, Joris Leroy, Corentin Proust, Marion Thiers, Marlène Boudry, Isabelle Grange, Laurent Lalami, Gilliane Bosson, Jean-Luc |
| Author_xml | – sequence: 1 givenname: Caroline orcidid: 0009-0002-9180-0646 surname: Maindet fullname: Maindet, Caroline organization: Pain Medicine Department, CHU Grenoble Alpes, Grenoble, France – sequence: 2 givenname: Joris surname: Giai fullname: Giai, Joris organization: Public Health Department, CHU Grenoble Alpes, Grenoble, France – sequence: 3 givenname: Corentin surname: Leroy fullname: Leroy, Corentin organization: Public Health Department, CHU Grenoble Alpes, Grenoble, France – sequence: 4 givenname: Marion surname: Proust fullname: Proust, Marion organization: Public Health Department, CHU Grenoble Alpes, Grenoble, France – sequence: 5 givenname: Gilliane surname: Lalami fullname: Lalami, Gilliane organization: Public Health Department, CHU Grenoble Alpes, Grenoble, France – sequence: 6 givenname: Isabelle surname: Boudry fullname: Boudry, Isabelle organization: Public Health Department, CHU Grenoble Alpes, Grenoble, France – sequence: 7 givenname: Marlène surname: Thiers fullname: Thiers, Marlène organization: Public Health Department, CHU Grenoble Alpes, Grenoble, France – sequence: 8 givenname: Jean-Luc surname: Bosson fullname: Bosson, Jean-Luc organization: Public Health Department, CHU Grenoble Alpes, Grenoble, France – sequence: 9 givenname: Laurent surname: Grange fullname: Grange, Laurent organization: Rheumatology Department, CHU Grenoble Alpes, Grenoble, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40971509$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1OwzAQhC1UREvhDRDykUupf5o44Yaq8iNV4tJ7tU3W1ODEwXaK8gy8NEYUidOuVp9mZ-acjFrXIiFXnN1yVsq532PfQHTWvQ7zdwS9KPITMuGLXMyYlGL0bx-T8xDeGGMZl8UZGS9YqXjGygn5WmltKqgGCm1NA2iMA3WaAm2MtabB6JF-wgFpg3UCLa3xYCqk2nnagWlpi713jat7C9G4lqZTh950e_SJdiGiAx_33kQT7pJu5V0I7oCe-vTSNSZgTaM3YC_IqQYb8PI4p2TzsNosn2brl8fn5f161mV5OSu1UgIXwJUuhM5kslwhlEoiINegFAelkRWiShkrxSSHvFSqUHKnBNdKTMnNr2zn3UePIW6ThwqthRZdH7ZSZCKTIlc_6PUR7Xcp_7bzpgE_bP_6E988zXsg |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. |
| Copyright_xml | – notice: The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. |
| DBID | NPM 7X8 |
| DOI | 10.1093/rheumatology/keaf486 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1462-0332 |
| ExternalDocumentID | 40971509 |
| Genre | Journal Article |
| GroupedDBID | --- -E4 .2P .I3 .XZ .ZR 08P 0R~ 18M 29P 2WC 354 4.4 48X 5RE 5VS 5WA 5WD 70D AABZA AACZT AAJKP AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAVAP AAWTL ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPTD ABQLI ABQNK ABVGC ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AGINJ AGKEF AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CS3 CZ4 DAKXR DILTD DU5 D~K E3Z EBS EE~ ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 JXSIZ KAQDR KOP KQ8 KSI KSN L7B M-Z MHKGH N9A NGC NOMLY NOYVH NPM O9- OAUYM OAWHX OBH OCZFY ODMLO OHH OJQWA OJZSN OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX RUSNO RW1 RXO TCURE TEORI TJX TR2 VVN WOQ X7H YAYTL YKOAZ YXANX ZKX ZY1 ~91 7X8 |
| ID | FETCH-LOGICAL-p569-9f772e4a17f82f53afecea973eae1fa771a7fe082c971c7031a6977873b721f72 |
| IEDL.DBID | 7X8 |
| ISSN | 1462-0332 |
| IngestDate | Sun Sep 28 08:50:05 EDT 2025 Sun Sep 21 01:51:09 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Medical device Painkiller Sleep Osteoarthritis Quality of life |
| Language | English |
| License | The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-p569-9f772e4a17f82f53afecea973eae1fa771a7fe082c971c7031a6977873b721f72 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0009-0002-9180-0646 |
| PMID | 40971509 |
| PQID | 3252532677 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3252532677 pubmed_primary_40971509 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-Sep-13 20250913 |
| PublicationDateYYYYMMDD | 2025-09-13 |
| PublicationDate_xml | – month: 09 year: 2025 text: 2025-Sep-13 day: 13 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Rheumatology (Oxford, England) |
| PublicationTitleAlternate | Rheumatology (Oxford) |
| PublicationYear | 2025 |
| SSID | ssj0005138 |
| Score | 2.4758148 |
| SecondaryResourceType | online_first |
| Snippet | To manage osteoarthritis (OA)-related pain, current guidelines recommend a combination of non-pharmacological and pharmacological treatments. The objective of... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| Title | Efficacy and safety of a millimetre wave medical device for pain neuromodulation in peripheral osteoarthritis: a crossover randomised trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40971509 https://www.proquest.com/docview/3252532677 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA6-EC--H-uLEbyW3SZt03oREcWDLh72sLdl2k5Y0W3rvsTf4J92knbxJAheeig0DOlk5ksm831CXHZSKU3cCTzDeNcLYkReUlHk-bmiVKdZgKlrFH7U3W7c7yfPzYHbpLlWuYiJLlDnZWbPyNtKhjJkrKH1dfXuWdUoW11tJDSWxapiKGO9Wvd_2MJD3ylZczCQXkcpuWidS1R7PKQZQ0J3dN1-JTRBHP0OMl2yud_6r5nbYrOBmXBT-8WOWKJiV6w_NYX0PfF1Z6kjMPsELHKYoKHpJ5QGEKwM0cuIpmOCD5wTjOpKDuRkYwowxoUKXwpwRJijMm_kv4BfWdJkx1LwBrZ1pGSvHDrOpCse16Vje18UODvmJbsX5eA0Q_ZF7_6ud_vgNboMXhVGiZcYRuQUoK9NLE2o2MSMMNGKkHyDWvuoDTG0yBLtZ5YfHyNGmbFWKW83jZYHYqUoCzoSgMT7szxTjDpMgIa3fmFIttSogjRBMi1xsZjlAdtlaxlYUDmbDH7muSUO6181qGp-joGl8GKcmxz_4esTsSGtoq8VhVCnYtXwoqczsZbNeXbG586f-Nl9fvoGOkXahw |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+safety+of+a+millimetre+wave+medical+device+for+pain+neuromodulation+in+peripheral+osteoarthritis%3A+a+crossover+randomised+trial&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Maindet%2C+Caroline&rft.au=Giai%2C+Joris&rft.au=Leroy%2C+Corentin&rft.au=Proust%2C+Marion&rft.date=2025-09-13&rft.issn=1462-0332&rft.eissn=1462-0332&rft_id=info:doi/10.1093%2Frheumatology%2Fkeaf486&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0332&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0332&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0332&client=summon |